TOI vs. SHLT, PTWO, CANOQ, CCM, HIMS, TDOC, AUNA, LFMD, AIRS, and TBRG
Should you be buying Oncology Institute stock or one of its competitors? The main competitors of Oncology Institute include SHL Telemedicine (SHLT), Pono Capital Two (PTWO), Cano Health (CANOQ), Concord Medical Services (CCM), Hims & Hers Health (HIMS), Teladoc Health (TDOC), Auna (AUNA), LifeMD (LFMD), AirSculpt Technologies (AIRS), and TruBridge (TBRG).
Oncology Institute (NASDAQ:TOI) and SHL Telemedicine (NASDAQ:SHLT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.
SHL Telemedicine has a net margin of 0.00% compared to Oncology Institute's net margin of -20.28%. SHL Telemedicine's return on equity of 0.00% beat Oncology Institute's return on equity.
Oncology Institute received 3 more outperform votes than SHL Telemedicine when rated by MarketBeat users. However, 100.00% of users gave SHL Telemedicine an outperform vote while only 66.67% of users gave Oncology Institute an outperform vote.
In the previous week, Oncology Institute had 2 more articles in the media than SHL Telemedicine. MarketBeat recorded 5 mentions for Oncology Institute and 3 mentions for SHL Telemedicine. Oncology Institute's average media sentiment score of 0.59 beat SHL Telemedicine's score of 0.29 indicating that Oncology Institute is being referred to more favorably in the media.
36.9% of Oncology Institute shares are held by institutional investors. Comparatively, 20.1% of SHL Telemedicine shares are held by institutional investors. 9.5% of Oncology Institute shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
SHL Telemedicine has lower revenue, but higher earnings than Oncology Institute.
Oncology Institute presently has a consensus target price of $2.25, indicating a potential upside of 355.28%. SHL Telemedicine has a consensus target price of $11.00, indicating a potential upside of 98.56%. Given Oncology Institute's higher possible upside, analysts plainly believe Oncology Institute is more favorable than SHL Telemedicine.
Summary
Oncology Institute beats SHL Telemedicine on 7 of the 13 factors compared between the two stocks.
Get Oncology Institute News Delivered to You Automatically
Sign up to receive the latest news and ratings for TOI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TOI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncology Institute Competitors List
Related Companies and Tools
